Diabetes
Refine Search
Pharmaceutical
UK pharma giant GlaxoSmithKline released a couple of news items yesterday, one slightly negative regarding a melanoma combination product filing in Europe and the other announcing approval of a new diabetes treatment. 27 March 2014
Pharmaceutical
Anglo-Swedish drug major AstraZeneca says that Japanese Ministry of Health, Labor and Welfare approved Forxiga (dapagliflozin in 5mg and 10mg tablets), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, as a once-daily oral treatment for type 2 diabetes. 24 March 2014
Pharmaceutical
On March 19, Oleg Musiy, the Minister of Health in Ukraine, signed the memorandum of understanding with representatives of pharmaceutical companies and authorized representatives of foreign insulin producers: Farmak JSC, INDAR PrJSC, PharmaLife and two Association of Pharmaceutical Research and Development (APRaD) member companies – the USA’s Eli Lilly and France’s Sanofi . 24 March 2014
Pharmaceutical
German family-owned drug major Boehringer Ingelheim and partner Eli Lilly of the USA have announce a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending approval of the investigational sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin. 23 March 2014
Pharmaceutical
The European Medicines agency’s Committee for Medicinal Products for Human Use has issued positive opinions for expanded use of Danish diabetes care giant Novo Nordisk’s Tresiba (insulin degludec) and Victoza (liraglutide) in type 2 diabetes. 21 March 2014
Pharmaceutical
The microvascular complications of diabetes pharmaceutical market value in the seven major countries (7MM: the USA, France, Germany, Italy, Spain, the UK and Japan) is expected to increase from $3.6 billion in 2012 to $6.4 billion by 2022, at a compound annual growth rate (CAGR) of 5.8%. 20 March 2014
Pharmaceutical
Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be listed on the Australian Pharmaceutical Benefits Scheme (PBS) from April 1, Health Minister Peter Dutton announced, noting that that improved access to these medicines would benefit many Australians and particularly families with sick children. 19 March 2014
Pharmaceutical
The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini spoke about pharma innovation in action at The Economist’s Pharma Summit in London on Thursday. 17 March 2014
Pharmaceutical
UK biopharma company GW Pharmaceuticals this morning provided an update on the company’s cannabinoid pipeline in the treatment of epilepsy, diabetes and schizophrenia. 17 March 2014
Pharmaceutical
Danish insulin giant Novo Nordisk revealed this morning that it is increasing its drug development capacity by investing 550 million Danish kroner ($100 million) in a new research and development facility in Bagsvaerd, Denmark. 14 March 2014
Biotechnology
US biotech firm Islet Sciences says it has signed a binding letter of intent to acquire Brighthaven Ventures d/b/a BHV Pharma in a stock transaction. 13 March 2014
Biotechnology
Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug delivery technology, HEPtune, says it has expanded the scope of its partnership with Danish insulin giant Novo Nordisk. 11 March 2014
Pharmaceutical
Anglo-Swedish drug major AstraZeneca’s type 2 diabetes drug Xigduo is now available in the UK. 11 March 2014
Pharmaceutical
Last week, the Ukraine Cabinet of Ministers (CMU) put off the beginning of price declaration on insulin till January 1, 2015, by adopting the Resolution on postponement of the Insulin Pilot Project and cancellation of CMU Res-ons № 743 and No 952. 10 March 2014
Pharmaceutical
Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese Ministry of Health, Labor and Welfare for trelagliptin succinate (SYR-472), a once weekly dosage treatment for type 2 diabetes. 9 March 2014
Pharmaceutical
There was disappointment today for US drug major Eli Lilly and family-owned German pharma firm Boehringer Ingelheim when the US Food and Drug Administration issued a complete response letter for the New Drug Application of the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. 5 March 2014
Pharmaceutical
Danish insulin giant Novo Nordisk has presented positive data at the Diabetes UK conference from its DUAL I and II (Dual Action of Liraglutide and Insulin Degludec in type 2 diabetes) studies. 5 March 2014
Pharmaceutical
Anglo-Swedish drug major AstraZeneca says the US Food and Drug Administration has approved the Bydureon Pen 2mg as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. 3 March 2014
Biotechnology
In an announcement to the Stock Exchange, Israeli firm Clal Biotechnology Industries said that, on February 25, Andromeda Biotech, a company owned by CBI (with a 96% fully diluted stake, once the repurchase of Andromeda shares from Teva Pharmaceutical Industries is completed) has signed a non-binding term sheet contemplating its sale to an unnamed US based pharmaceutical company. 28 February 2014
Pharmaceutical
New medicines for glaucoma, diabetes and advanced soft tissue sarcoma have been approved for listing on Australia’s Pharmaceutical Benefits Scheme (PBS). Announcing the approval, Minister for Health Peter Dutton said the PBS subsidies would make the medicines more affordable for Australians who needed them. 27 February 2014
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze